| 摘要 |
According to the invention beta-tubulin, as well as a 65 kDa polypeptide present in pancreatic beta-cells, have been identified as molecular targets for sulfonylurea compounds. These findings enable for the identification of new insulin secretagogues. The invention thus relates to the use of sulfonylurea compounds, such as e.g. glibenclamide, in methods for identification of compounds binding the 65 kDa polypeptide or tubulin, or stimulating tubulin polymerization and/or turnover, thereby stimulating insulin secretion.
|
